Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arnica Tincture for Cutaneous Leishmaniasis
NCT05094908Phase 1Active, not recruiting
- Sponsor
- Universidad de Antioquia
- Start
- May 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of arnica tincture in cutaneous leishmaniasis (CL) (2 arms), sponsored by Universidad de Antioquia. Primary endpoint: Initial post-treatment healing at 90 days. Started May 2023; status: active, not recruiting.
02
Drugs
arnica tincture
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT05094908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05094908.